BMX-001 free base

Star0

DB17516InvestigationalSmall molecule

BMX-001 free base: Overview.

Mechanism: Pharmacologically active on Superoxide dismutase
Curator reviewed
Formula / weight: C₆₄H₇₆MnN₈O₄ · 1076.299 g/mol (avg)
Also known as: Manganese(5+), ((2,2',2'',2'''-(21h,23h-porphine-5,10,15,20-tetrayl-.kappa.n21,.kappa.n22,.kappa.n23,.kappa.n24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, (sp-4-1)-

Resolves to

Compound

UNIIJ06K64323RCAS1379866-50-8

Structure

InChIKeyCZXJDWRMJZZOTQ-UHFFFAOYSA-NSMILES

[Mn+3].CCCCOCC[N+]1=CC=CC=C1\C1=C2/C=CC(=N2)\C(=C2/[N-]\C(\C=C2)=C(/C2=N/C(/C=C2)=C(\C2=CC=C1[N-]2)C1=CC=CC=[N+]1CCOCCCC)C1=CC=CC=[N+]1CCOCCCC)\C1=CC=CC=[N+]1CCOCCCC

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of BMX-001 free base, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account